There will be no crowded lobbies or $100 chair rentals at this year’s J.P. Morgan Healthcare Conference. But the trillion-dollar life sciences industry’s biggest annual meeting, forced onto Zoom by Omicron, will still attract attention from around the world as investors, executives, and others look to answer critical questions about the future of sectors like biotech and health tech.
Is there a second act for mRNA companies? Was teletherapy just a pandemic fad? Can Biogen salvage its foundering treatment for Alzheimer’s disease? And will 2022 be the year of the buyout?
Create a display name to comment
This name will appear with your comment